North America Colorectal Cancer Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The North America Colorectal Cancer Screening Market is segmented by Screening Tests (Stool-based Tests, Colonoscopy, CT Colonography (Virtual Colonoscopy), Flexible Sigmoidoscopy, and Others), End User, and Geography.

Market Snapshot

Image 1_North America Colorectal Cancer Screening Market-
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The North America colorectal cancer screening market is expected to observe good growth due to the advent of efficacious genetic tests, an increase in the prevalence of colorectal cancer, and increasing cancer prevention initiatives.

The increasing incidence of colorectal cancer (CRC) is found to be the third most prevalent form of cancer. It accounts for almost a tenth of all cancer incidences worldwide and its incidence has been increasing over the last couple of years. Furthermore, the introduction of novel colorectal tests that use biomarkers such as tumor M2-PK marker or which screen for colorectal cancer using methylated genes for screening has witnessed growth in the market. Thus the growing cases of colorectal cancer in various parts of the world are found boosting the need for regular screening, thereby propelling the growth of the global colorectal cancer screening market.

In addition, the increasing awareness about genetic screening methods and advantages for undergoing these tests (not only for early detection and treatment, but also for the removal of precancerous cells, which are much cheaper than the usual run of chemotherapy) are driving the colorectal cancer screening market.

Scope of the Report

As per the scope of the report, colorectal cancer (CRC) is known as bowel cancer and colon cancer. Colorectal cancer accounts for a substantial share of cancer-related mortality in several countries that have risen over the past few decades. Being the third most common cancer and the fourth most common cause of cancer death, colorectal cancer accounts for substantial morbidity and mortality worldwide. Therefore the colorectal cancer screening tests use kits and various medical devices for diagnosing the cancer.

By Screening Tests
Stool-based Tests
Fecal Immunochemical Test (FIT)
Guaiac-based Fecal Occult Blood Test (gFOBT)
Stool DNA Test
Colonoscopy
CT Colonography (Virtual Colonoscopy)
Flexible Sigmoidoscopy
Others
By End User
Hospitals
Independent Diagnostic Labs
Other End Users
Geography
North America
United States
Canada
Mexico

Report scope can be customized per your requirements. Click here.

Key Market Trends

Guaiac Fecal Occult Blood Test (gFOBT) is Expected to be the Fastest Growing Segment, Over the Forecast Period

The guaiac fecal occult blood test (gFOBT) is one of the tests that is used to detect colorectal cancer. It involves the detection of hidden blood in the feces, and identifies the presence of cancer cells or tumors in the colon or rectum. The presence of blood in the stool may be a sign of colorectal cancer or other problems, such as polyps, ulcers, or hemorrhoids.

As per the American College of Gastroenterology (ACG), the procedural volumes for colorectal (CRC) screening with gFOBT have decreased modestly. However, the factors that are driving the overall market are its ease of availability, low cost, and coverage in the insurance, along with being sold as over-the-counter. Hence over the forecast period, the growth of this segment is mainly attributed to the growing cancer burden, ease of availability, and low cost of the products.

North America Colorectal Cancer Screening Market 2.png

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of many small and large market players. Some of the market players are Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Novigenix SA, Siemens Healthineers, and Sysmex Corporation.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Advent of Efficacious Genetic Tests

      2. 4.2.2 Increase in Prevalence of Colorectal Cancer

      3. 4.2.3 Increasing Cancer Prevention Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Screening Tests Costs

      2. 4.3.2 Inadequate Healthcare Access in Developing Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Screening Tests

      1. 5.1.1 Stool-based Tests

        1. 5.1.1.1 Fecal Immunochemical Test (FIT)

        2. 5.1.1.2 Guaiac-based Fecal Occult Blood Test (gFOBT)

        3. 5.1.1.3 Stool DNA Test

      2. 5.1.2 Colonoscopy

      3. 5.1.3 CT Colonography (Virtual Colonoscopy)

      4. 5.1.4 Flexible Sigmoidoscopy

      5. 5.1.5 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Independent Diagnostic Labs

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Clinical Genomics Technologies Pty Ltd

      3. 6.1.3 Epigenomics Inc.

      4. 6.1.4 Exact Sciences Corporation

      5. 6.1.5 F. Hoffmann-La Roche AG

      6. 6.1.6 Hemosure Inc.

      7. 6.1.7 Novigenix SA

      8. 6.1.8 Quidel Corporation

      9. 6.1.9 Siemens Healthineers AG

      10. 6.1.10 Sysmex Corporation

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Colorectal Cancer Screening Market market is studied from 2018 - 2026.

The North America Colorectal Cancer Screening Market is growing at a CAGR of 4% over the next 5 years.

Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, Clinical Genomics Technologies Pty Ltd., Hemosure Inc. are the major companies operating in North America Colorectal Cancer Screening Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!